BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 6233398)

  • 1. Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer.
    Cavalli F; Goldhirsch A; Jungi F; Martz G; MermillodB ; Alberto P
    J Clin Oncol; 1984 May; 2(5):414-9. PubMed ID: 6233398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral versus intramuscular high-dose medroxyprogesterone acetate (HD-MPA) in advanced breast cancer. A randomized study of the Belgian Society of Medical Oncology.
    Paridaens R; Becquart D; Michel J; Vanderlinden B; Longueville J; Majois F; Beauduin M; Focan C; Wildiers J; Bernheim J
    Anticancer Res; 1986; 6(5):1089-94. PubMed ID: 2948441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose medroxyprogesterone acetate in advanced breast cancer. Clinical and pharmacokinetic study with a combined oral and intramuscular regimen.
    Becher R; Miller AA; Höffken K; Gerhold U; Hirche H; Schmidt CG
    Cancer; 1989 May; 63(10):1938-43. PubMed ID: 2522811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral high-dose medroxyprogesterone acetate versus tamoxifen. A randomized crossover trial in postmenopausal patients with advanced breast cancer.
    van Veelen H; Willemse PH; Tjabbes T; Schweitzer MJ; Sleijfer DT
    Cancer; 1986 Jul; 58(1):7-13. PubMed ID: 2939943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Oral high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer: a dose-response evaluation].
    Tominaga T; Izuo M; Nomura Y; Kubo K; Abe O; Enomoto K; Takatani O
    Gan To Kagaku Ryoho; 1982 Nov; 9(11):1994-2004. PubMed ID: 6223590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer.
    Beex L; Burghouts J; van Turnhout J; Breed W; Hillen H; Holdrinet A; Boetius G; Hoogendoorn G; Doesburg W; Verhulst M
    Cancer Treat Rep; 1987 Dec; 71(12):1151-6. PubMed ID: 3690524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medroxyprogesterone acetate and prednisone in advanced breast cancer. A randomized trial.
    Jakobsen A; Frederiksen PL; Møller KA; Andersen AP; Brincker H; Dombernowsky P; Hansen PV; Hesselius I; Kjaer M
    Eur J Cancer Clin Oncol; 1986 Sep; 22(9):1067-72. PubMed ID: 2946583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical investigation of oral high-dose medroxyprogesterone acetate (MPA) in advanced breast cancer--double-blind controlled study: Japanese Group for MPA Treatment of Breast Cancer].
    Izuo M; Tominaga T; Yoshida M; Nomura Y; Abe O; Enomoto K; Kubo K; Takatani O
    Gan No Rinsho; 1985 May; 31(5):487-93. PubMed ID: 3160869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors].
    Nomura Y; Tashiro H; Hisamatsu K; Toi M
    Gan To Kagaku Ryoho; 1988 Mar; 15(3):513-8. PubMed ID: 2964811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose medroxyprogesterone acetate (MPA) treatment in advanced breast cancer. A review.
    Ganzina F
    Tumori; 1979 Oct; 65(5):563-85. PubMed ID: 390798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women.
    Klaassen DJ; Rapp EF; Hirte WE
    Cancer Treat Rep; 1976 Mar; 60(3):251-3. PubMed ID: 1260780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study.
    Muss HB; Case LD; Atkins JN; Bearden JD; Cooper MR; Cruz JM; Jackson DV; O'Rourke MA; Pavy MD; Powell BL
    J Clin Oncol; 1994 Aug; 12(8):1630-8. PubMed ID: 8040675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a dose-response evaluation.
    Cuna GR; Calciati A; Strada MR; Bumma C; Campio L
    Tumori; 1978 Apr; 64(2):143-9. PubMed ID: 354147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evaluation of high-dose medroxyprogesterone acetate (MPA) therapy in women with advanced breast cancer.
    Johnson JR; Priestman TJ; Fotherby K; Kelly KA; Priestman SG
    Br J Cancer; 1984 Sep; 50(3):363-6. PubMed ID: 6235831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The medroxyprogesterone acetate serum level following various medroxyprogesterone acetate dose schedules in gynecologic oncology].
    Husslein P; Egarter C; Eppel W; Salzer H; Spona J
    Zentralbl Gynakol; 1988; 110(20):1277-82. PubMed ID: 2977043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group.
    Byrne MJ; Gebski V; Forbes J; Tattersall MH; Simes RJ; Coates AS; Dewar J; Lunn M; Flower C; Gill PG; Stewart J
    J Clin Oncol; 1997 Sep; 15(9):3141-8. PubMed ID: 9294477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effect of high-dose medroxyprogesterone acetate (HD-MPA) on hematological toxicity induced by chemotherapy for advanced solid tumors: a multicentric controlled clinical trial. MPA-Hematology Italian Cooperative Group.
    Chemioterapia; 1986 Apr; 5(2):134-9. PubMed ID: 2871945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase III trial of oral high-dose medroxyprogesterone acetate (MPA) versus mepitiostane in advanced postmenopausal breast cancer.
    Izuo M; Yoshida M; Tominaga T; Abe O; Enomoto K; Nomura Y; Kubo K; Takatani O
    Cancer; 1985 Dec; 56(11):2576-9. PubMed ID: 2932213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of breast cancer with medroxyprogesterone acetate.
    Muggia FM; Cassieth PA; Ochoa M; Flatow FA; Gellhorn A; Hyman GA
    Ann Intern Med; 1968 Feb; 68(2):328-37. PubMed ID: 4306126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medroxyprogesterone acetate at very high doses in postmenopausal advanced breast cancer patients.
    Pannuti F; Longhi A; Martoni A; Piana E; Baroni M
    Chemioterapia; 1987 Dec; 6(6):396-8. PubMed ID: 2963702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.